Tumour angiogenesis: Vascular growth and survival

APMIS

Volumn 112, Issue 7-8, 2004, Pages 431-440

  Giatromanolaki, Alexandra ^a,b   Sivridis, Efthimios ^a   Koukourakis, Michael I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DUTh ^*  (Greece)

Author keywords

Angiogenesis; Tumour angiogenic ability (TAA); Vascular survival ability (VSA)

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CD31 ANTIGEN; CYTOKINE; KI 67 ANTIGEN; NITRIC OXIDE; OXYGEN; PROTEIN BCL 2; SCATTER FACTOR; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ACIDITY; ANGIOGENESIS; APOPTOSIS; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL INVASION; CELL PROLIFERATION; COLORECTAL CARCINOMA; EPITHELIUM TUMOR; GLYCOLYSIS; HUMAN; HYPOXIA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; REVIEW; STROMA; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; URINARY BLADDER NEOPLASMS;

EID: 9944246963     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2004.apm11207-0804.x     Document Type: Review

References (67)

1. Folkman J. Tumour angiogenesis. Adv Cancer Res 1985;43:175-203.
2. Gasparini G, Harris AL. Clinical importance of the determination of tumour angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995;13:765-82.
3. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
4. Giatromanolaki A, Koukourakis M, O'Byrne K, Fox S, Whitehouse R, Talbot DC, Harris AL, Gatter KC. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996;79:80-8.
5. Giatromanolaki A, Sivridis E, Koukourakis MI, Georgoulias V, Gatter KC, Harris AL. Intra-tumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas? Oncol Res 1999;11:205-12.
6. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, Papadimitriou C, Georgoulias V, Gatter KC, Harris AL, Koukourakis MI. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999;86:1421-30.
7. Giatromanolaki A, Sivridis E, Koukourakis MI, Polychronidis A, Simopoulos C. Prognostic role of angiogenesis in operable carcinoma of the gallbladder. Am J Clin Oncol 2002;25:38-41.
8. Koukourakis MI, Giatromanolaki A, Fountzilas G, Sivridis E, Gatter KC, Harris AL. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res 2000;6:381-9.
9. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treatment 1995;36:193-204.
10. Riedel F, Gotte K, Bergler W, Rojas W, Hormann K. Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer. Head Neck 2000;22:183-9.
11. Sivridis E, Giatromanolaki A, Koukourakis MI, Bicknell R, Harris AL, Gatter KC. Thymidine phosphorylase expression in endometrial carcinomas. Clin Exp Met 1999;17:445-50.
12. Giatromanolaki A, Koukourakis MI, Stathopoulos GP, Kapsoritakis A, Paspatis G, Kakolyris S, Sivridis E, Georgoulias V, Harris AL, Gatter KC. Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. Oncol Res 2000;12:33-41.
13. Sivridis E, Giatromanolaki A, Anastasiadis P, Georgiou L, Gatter KC, Harris AL, Bicknell R, Koukourakis MI. Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. J Pathol 2002;196:416-22.
14. Thompson WD, Shiach KJ, Fraser RA, McIntosh LC, Simpson JG. Tumours acquire their vascularity by vesssel incorporation, not vessel ingrowth. J Pathol 1987;151:323-32.
15. Jain RK. Transport of molecules across tumour vasculature. Cancer Met Rev 1987;6:559-594.
16. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
17. Jain RK. Transport of macromolecules in tumour microcirculation. Biotech Prog 1985;1:81-94.
18. McCurley CR, Shivers RR, Del Maestro RF. Quantitative comparison of the morphology of the microvasculature of primary lung lesions and metastatic brain tumours. J Submicrosc Cytol Pathol 1998;30:257-69.
19. Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999;58:312-28.
20. Miodonski AJ, Bugajski A, Litwin JA, Piasecki Z. Vascular architecture of human urinary bladder carcinoma: a SEM study of corrosion casts. Virchows Arch 1998;433:145-51.
21. Sivridis E, Giatromanolaki A, Koukourakis MI. The vascular network of tumours - what is it not for? J Pathol 2003;201:173-80.
22. Sivridis E, Giatromanolaki A, Koukourakis MI. "Stromatogenesis" and tumor progression. Int J Surg Pathol 2004;12:1-9.
23. Giatromanolaki A, Koukourakis ML, Kakolyris S, Turley H, O'Byrne K, Scott PAE, Pezzella F, Georgoulias V, Harris AL, Gatter KC. Vascular endothelial growth factor, wild-type p53 and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998;4:3017-24.
24. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1995;1:961-4.
25. Takahashi Y, Bucana CD, Liu W, Yoneda J, Kitadai Y, Clearly KR, Ellis LM. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996;88:1146-51.
26. Koukourakis MI, Giatromanolaki A, O'Byrne K, Comley M, Whitehouse R, Talbot DC, Gatter KC, Harris AL. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small cell lung cancer. Br J Cancer 1997;4:477-81.
27. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-25.
28. Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, Wilke CA, Strieter RM. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994;179:1409-15.
29. Giatromanolaki A, Koukourakis M, O'Byrne K, Fox S, Whitehouse R, Talbot D, Harris AL, Gatter KC. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996;179:80-8.
30. Giatromanolaki A, Koukourakis MI, Kakolyris S, Mavroudis D, Kouroussis C, Mavroudi C, Perraki M, Sivridis E, Georgoulias V. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int J Cancer 2004;108:620-7.
31. Giatromanolaki A, Sivridis E, Koukourakis MI, Georgoulias V, Gatter KC, Harris AL. Intra-tumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas? Oncol Res 1999;11:205-12.
32. Giatromanolaki A, Koukourakis MI, Georgoulias V, Gatter KC, Harris AL, Fountzilas G. Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer. Int J Cancer 1999;80:810-7.
33. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, Papadimitriou C, Georgoulias V, Gatter KC, Harris AL, Koukourakis MI. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999;86:1421-30.
34. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
35. Fox SB, Gatter KC, Bicknell R, Going JJ, Stanton P, Cooke TG, Harris AL. Relationship of endothelial cell proliferation to tumour vascularity in human breast cancer. Cancer Res 1993;53:4161-3.
36. Koukourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I. Cancer vascularization: implications in radiotherapy? Int J Radiat Oncol Biol Phys 2000;48:545-3.
37. Brekken RA, Huang X, King SW, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998;58:1952-9.
38. Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoulias V, Gatter KC, Harris AL. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000;60:3088-95.
39. Giatromanolaki A, Koukourakis MI, Sivridis E, O'Byrne K, Gatter KC, Harris AL. 'Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J Pathol 2000;192:140-9.
40. Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, Harris AL; Tumour and Angiogenesis Research Group. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003;89:877-85.
41. Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. Microsc Res Tech 2002;59:41-8.
42. Gaja G, Cajone F, Ferrero ME, Bernelli-Zazzera A. Anaerobic glycolysis and patterns of glycolytic intermediates during liver carcinogenesis and in hepatoma. J Natl Cancer Inst 1970;44:1269-80.
43. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, Laughner E, Ravi R, Simons J, Taghavi P, Zhong H. 'The metabolism of tumours': 70 years later. Novartis Found Symp 2001;240:251-60; discussion 260-4.
44. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001;28(2 Suppl 8):36-41.
45. Shim H, Chun YS, Lewis BC, Dang CV. A unique glucose-dependent pathway induced by c-Myc. Proc Natl Acad Sci USA 1998;95:1511-16.
46. Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, Caro J. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 2002;277:6183-7.
47. Koukouraki S, Koukourakis MI, Vagios E, Velidaki A, Tsiftsis D, Karkavitsas N. The role of 99m Tc-sestamibi scintimammography and colour Doppler ultrasonography in the evaluation of breast lesions. Nucl Med Commun 2001;22:1243-8.
48. Koukourakis MI. Tumour angiogenesis and response to radiotherapy. Anticancer Res 2001;21:4285-300.
49. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001;85;273-8.
50. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280:1375-86.
51. 2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins 1978;16:373-88.
52. Servos S, Zachary I, Martin JF. VEGF modulates NO production: the basis of a cytoprotective effect? Cardiovasc Res 1999;41:509-10.
53. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Hepatocyte growth factor prevents endothelial cell death through inhibition of bax translocation from cytosol to mitochondrial membrane. Diabetes 2002;51:2604-11.
54. Sata M, Kakoki M, Nagata D, Nishimatsu H, Suzuki E, Aoyagi T, Sugiura S, Kojima H, Nagano T, Kangawa K, Matsuo H, Omata M, Nagai R, Hirata Y. Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism. Hypertension 2000;36:83-8.
55. Harfouche R, Hassessian HM, Guo Y, Faivre V, Srikant CB, Yancopoulos GD, Hussain SN. Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 2002;64:135-47.
56. Koukouraki S, Koukourakis MI, Vagios E, Velidaki A, Tsiftsis D, Karkavitsas N. The role of 99m Tc-sestamibi scintimammography and colour Doppler ultrasonography in the evaluation of breast lesions. Nucl Med Commun 2001;22:1243-8.
57. Koukourakis MI. Tumour angiogenesis and response to radiotherapy. Anticancer Res 2001;21:4285-300.
58. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001;85:273-8.
59. Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC, Altieri DC. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001;158:1757-65.
60. Giatromanolaki A, Sivridis E, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, Koukourakis MI. Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer. Clin Exp Metastasis 2002;19:673-9.
61. Giatromanolaki A, Sivridis E, Minopoulos G, Polychronidis A, Manolas C, Simopoulos C, Koukourakis MI. Differential assessment of vascular survival ability and tumor angiogenic activity in colorectal cancer. Clin Cancer Res 2002;8:1185-91.
62. Papadopoulos I, Giatromanolaki A, Koukourakis MI, Sivridis E. Tumour angiogenic activity (TAA) and vascular survival ability (VSA) in bladder carcinoma. J Clin Pathol 2004;57:250-5.
63. Thompson WD. Tumour versus patient: vascular and tumour survival versus prognosis. J Pathol 2001;193:425-6.
64. Williams CS, Leek RD, Robson AM, Banerji S, Prevo R, Harris AL, Jackson DG. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 2003;200:195-206.
65. Clarijs R, Ruiter DJ, de Waal RM. Lymphangiogenesis in malignant tumours: Does it occur? J Pathol 2001;193:143-6.
66. Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 2001;40:5542-7.
67. Geschwind JFH, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intrarterial injection of a potent inhibitor of ATP production. Cancer Res 2002;62:3909-13.